Nicholas J Vogelzang

Nicholas J Vogelzang

UNVERIFIED PROFILE

Are you Nicholas J Vogelzang?   Register this Author

Register author
Nicholas J Vogelzang

Nicholas J Vogelzang

Publications by authors named "Nicholas J Vogelzang"

Are you Nicholas J Vogelzang?   Register this Author

100Publications

3934Reads

7Profile Views

Adjuvant Androgen-Deprivation Therapy for Prostate Cancer: Should Docetaxel Be Added?

JAMA Oncol 2019 May;5(5):633-634

Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2018.6604DOI Listing
May 2019

Bladder Tumors with Mixed Histology: What Is the Basis for the Heterogeneity?

Eur Urol 2018 12 28;74(6):754-755. Epub 2018 Sep 28.

Department of Medical Oncology, School of Medicine, University of Nevada, Las Vegas, NV, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03022838183071
Publisher Site
http://dx.doi.org/10.1016/j.eururo.2018.09.031DOI Listing
December 2018

Predictors of Long-Term Response With Pazopanib in Patients With Advanced Renal-Cell Carcinoma.

Clin Genitourin Cancer 2018 08 23;16(4):293-297. Epub 2018 Mar 23.

The US Oncology Network/McKesson Specialty Health, The Woodlands, TX.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15587673183021
Publisher Site
http://dx.doi.org/10.1016/j.clgc.2018.03.005DOI Listing
August 2018

Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma.

Mayo Clin Proc 2018 08 24;93(8):1026-1033. Epub 2018 May 24.

Department of Cancer Biostatistics, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, and University of South Carolina Arnold School of Public Health, Columbia, SC.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00256196183018
Publisher Site
http://dx.doi.org/10.1016/j.mayocp.2018.01.032DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6077096PMC
August 2018

Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer.

J Clin Oncol 2018 06 28;36(16):1579-1587. Epub 2018 Mar 28.

David J. Vaughn, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Joaquim Bellmunt and Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA; Yves Fradet, CHU de Québec-Université Laval, Quebec City, Quebec, Canada; Jae Lyun Lee, Asan Medical Center and University of Ulsan College of Medicine, Seoul, Republic of Korea; Lawrence Fong, University of California, San Francisco, San Francisco; David I. Quinn, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Miguel A. Climent, Fundación Instituto Valenciano de Oncología, Valencia, Spain; Daniel P. Petrylak, Smilow Cancer Hospital, Yale University, New Haven, CT; Andrea Necchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan; Cora N. Sternberg, San Camillo and Forlanini Hospitals, Rome, Italy; Winald Gerritsen, Radboud University Medical Center, Nijmegen; Ronald de Wit, Erasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands; Howard Gurney, Westmead Hospital and Macquarie University, Sydney, New South Wales, Australia; Stephane Culine, Hôpital Saint-Louis, Paris, France; Yabing Mai, Haojie Li, and Rodolfo F. Perini, Merk & Co., Inc., Kenilworth, NJ; and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.76.9562
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.76.9562DOI Listing
June 2018

Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921.

J Clin Oncol 2018 05 6;36(15):1498-1504. Epub 2018 Apr 6.

Maha Hussain, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL; Catherine M. Tangen, Fred Hutchinson Cancer Research Center; Daniel W. Lin, University of Washington, Seattle, WA; Ian M. Thompson Jr, University of Texas Health Science Center, San Antonio; Gregory P. Swanson, Baylor Scott and White Health, Temple, TX; David P. Wood, Beaumont Physician Partners and Clinical Faculty, Royal Oak; Wael Sakr, Wayne State University School of Medicine, Detroit, MI; Nancy A. Dawson, Lombardi Comprehensive Cancer Center, Washington, DC; Naomi B. Haas, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA; Thomas W. Flaig, E. David Crawford, and L. Michael Glode, University of Colorado Cancer Center, Denver, CO; Tanya B. Dorff and David I. Quinn, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; and Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.4126DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5959197PMC
May 2018

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.

J Clin Oncol 2018 04 31;36(11):1080-1087. Epub 2018 Jan 31.

Christos E. Kyriakopoulos, Glenn Liu, and David F. Jarrard, University of Wisconsin (UW) School of Medicine and Public Health and UW Carbone Cancer Center, Madison, WI; Yu-Hui Chen and Christopher J. Sweeney, Dana-Farber Cancer Institute; Yu-Hui Chen, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group; Christopher J. Sweeney, Harvard Medical School, Boston, MA; Michael A. Carducci, Noah M. Hahn, and Mario Eisenberger, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD; Daniel H. Shevrin, NorthShore University HealthSystem, Evanston; Maha Hussain, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL; Robert Dreicer, University of Virginia Cancer Center, Charlottesville, VA; Manish Kohli, Mayo Clinic, Rochester, MN; Elizabeth R. Plimack, Fox Chase Cancer Center, Temple Health, Philadelphia, PA; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Joel Picus, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO; Matthew M. Cooney, Seidman Cancer Center, University Hospitals Cleveland Medical Center; Jorge A. Garcia, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; and Robert S. DiPaola, University of Kentucky College of Medicine, Lexington, KY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.3657DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891129PMC
April 2018

Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.

J Clin Oncol 2018 02 20;36(4):376-382. Epub 2017 Dec 20.

Lauren C. Harshman and Christopher J. Sweeney, Dana-Farber Cancer Institute, Harvard Medical School; Yu-Hui Chen, Dana-Farber Cancer Institute, Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group, Boston, MA; Glenn Liu and David Jarrard, University of Wisconsin School of Medicine and Public Health and Carbone Cancer Center, Madison, WI; Michael A. Carducci, Noah Hahn, and Mario Eisenberger, Johns Hopkins University, Baltimore, MD; Robert Dreicer, University of Virginia Cancer Center, Charlottesville, VA; Jorge A. Garcia, Cleveland Clinic Taussig Cancer Institute; Matthew Cooney, University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland, OH; Maha Hussain, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago; Daniel Shevrin, NorthShore University Health System, Evanston, IL; Manish Kohli, Mayo Clinic, Rochester, MN; Elizabeth R. Plimack, Fox Chase Cancer Center, Temple Health, Philadelphia, PA; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Joel Picus, Siteman Cancer Center, Washington University School of Medicine, St Louis, MO; and Robert Dipaola, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.75.3921
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.75.3921DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805480PMC
February 2018

Molecular Characterization of Bladder Cancer in Smokers versus Nonsmokers.

Eur Urol Focus 2018 01 24;4(1):94-97. Epub 2016 Jun 24.

Department of Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2016.06.011DOI Listing
January 2018

Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.

J Immunother Cancer 2018 01 29;6(1). Epub 2018 Jan 29.

Department of Hematology & Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Ave, Desk CA60, Cleveland, OH, 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-018-0319-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789686PMC
January 2018

Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours.

Eur J Cancer 2017 11 20;86:296-304. Epub 2017 Oct 20.

Early Drug Development Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.09.011DOI Listing
November 2017

Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma.

Eur Urol 2017 10 14;72(4):557-564. Epub 2017 Apr 14.

Department of Medical Oncology, Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2017.03.046DOI Listing
October 2017

A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma.

Eur J Cancer 2017 09 26;83:229-236. Epub 2017 Jul 26.

Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.06.018DOI Listing
September 2017

Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases.

Expert Rev Clin Pharmacol 2017 Aug 3;10(8):809-819. Epub 2017 Jul 3.

a Division of Hematology/Oncology , Comprehensive Cancer Centers of Nevada , Las Vegas , NV , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2017.1345624DOI Listing
August 2017

Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USA.

Int J Urol 2017 04 2;24(4):272-278. Epub 2017 Mar 2.

US Oncology Research, Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/iju.13314DOI Listing
April 2017

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

N Engl J Med 2017 03 17;376(11):1015-1026. Epub 2017 Feb 17.

From Dana-Farber Cancer Institute, Boston (J.B., T.K.C.); Parc de Salut Mar, Hospital del Mar Medical Research Institute, Barcelona (J.B.), and Fundación Instituto Valenciano de Oncología, Valencia (M.A.C.) - both in Spain; Erasmus MC Cancer Institute, Rotterdam (R.W.), and Radboud University Medical Center, Nijmegen (W.G.) - both in the Netherlands; Abramson Cancer Center, University of Pennsylvania, Philadelphia (D.J.V.); Centre Hospitalier Universitaire de Québec-Université Laval, Quebec, QC, Canada (Y.F.); Asan Medical Center and University of Ulsan College of Medicine, Seoul, South Korea (J.-L.L.); the University of California, San Francisco, San Francisco (L.F.); Comprehensive Cancer Centers of Nevada, Las Vegas (N.J.V.); Smilow Cancer Hospital, Yale University, New Haven, CT (D.P.P.); Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (A.N.); Westmead Hospital and Macquarie University, Sydney (H.G.); the University of Southern California Norris Comprehensive Cancer Center and Hospital, Los Angeles (D.I.Q.); Hôpital Saint-Louis, Paris (S.C.); San Camillo and Forlanini Hospitals, Rome (C.N.S.); Merck, Kenilworth, NJ (Y.M., C.H.P., R.F.P.); and Memorial Sloan Kettering Cancer Center, New York (D.F.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1613683DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635424PMC
March 2017

A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.

Cancer Treat Rev 2017 Mar 2;54:58-67. Epub 2017 Feb 2.

Comprehensive Cancer Centers of Nevada, Las Vegas, NV, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2017.01.007DOI Listing
March 2017

Future Challenges for Drug Development in Renal Cell Carcinoma.

J Clin Oncol 2017 02 19;35(6):577-579. Epub 2016 Dec 19.

Brian I. Rini, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; and Nicholas J. Vogelzang, US Oncology Research, Comprehensive Cancer Centers of Nevada, Las Vegas, NV.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.0673DOI Listing
February 2017

Cardiovascular adverse effects of targeted antiangiogenic drugs: mechanisms and management.

Future Oncol 2016 22;12(8):1067-80. Epub 2016 Feb 22.

University of Nevada School of Medicine & US Oncology/Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.16.4DOI Listing
December 2016

Chemotherapy following radium-223 dichloride treatment in ALSYMPCA.

Prostate 2016 07 23;76(10):905-16. Epub 2016 Mar 23.

Academic Urology Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, Surrey, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pros.23180DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5071661PMC
July 2016

Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon?

Future Oncol 2015 ;11(16):2299-306

University of Nevada School of Medicine & US Oncology/Comprehensive Cancer Centers of Nevada, Las Vegas, NV 89014, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.15.162DOI Listing
May 2016

Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial.

J Clin Oncol 2016 05 29;34(13):1500-9. Epub 2016 Feb 29.

Daniel P. Petrylak, Yale University Cancer Center, New Haven, CT; Scott T. Tagawa, Weill Cornell Medical College, New York; David Shaffer, New York Oncology Hematology, Albany, NY; Manish Kohli, Mayo Clinic, Rochester, MN; Andrea Eisen, Sunnybrook Health Sciences Centre; Srikala S. Sridhar, Princess Margaret Hospital, Toronto; Christina Canil, Ottawa Hospital Cancer Centre, Ottawa, Ontario; Kim N. Chi, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Alexander Spira, Virginia Cancer Specialists, Fairfax, VA; Alexander Spira, John M. Burke, David Shaffer, and Nicholas J. Vogelzang, US Oncology Research, The Woodlands, TX; Evan Y. Yu, University of Washington Medical Center and Fred Hutchinson Cancer Research Center, Seattle, WA; John M. Burke, Rocky Mountain Cancer Centers, Aurora, CO; Chong-Xian Pan, University of California-Davis Medical Center, Sacramento; David I. Quinn, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; Jenny J. Kim, Johns Hopkins University, Baltimore, MD; Jeanny B. Aragon-Ching, George Washington University Medical Center, Washington, DC; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Shande Tang, Hui Zhang, Christopher T. Cavanaugh, Ling Gao, and John S. Kauh, Eli Lilly, Bridgewater, NJ; and Richard A. Walgren, Eli Lilly, Indianapolis, IN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.0218DOI Listing
May 2016

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.

J Clin Oncol 2016 05 7;34(14):1652-9. Epub 2016 Mar 7.

Susan Halabi, Hua Ma, Nicole C. Solomon, and Andrew J. Armstrong, Duke University, Durham, NC; William Kevin Kelly, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA; Haojin Zhou, Merck, Beijing, China; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France; Catherine M. Tangen, Southwest Oncology Group Statistical Center; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Victoria, Australia; Daniel P. Petrylak, Yale Cancer Center, New Haven, CT; Maha Hussain, University of Michigan, Ann Arbor, MI; Nicholas J. Vogelzang, US Oncology, Las Vegas, NV; Ian M. Thompson, University of Texas at San Antonio, San Antonio; John C. Araujo and Christopher J. Logothetis, The University of Texas MD Anderson Cancer Center, Houston, TX; Kim N. Chi, British Columbia Cancer Agency-Vancouver Cancer Centre, Vancouver, British Columbia; Ian F. Tannock, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Johann de Bono, Institute for Cancer Research, Royal Marsden Hospital, Sutton, Surrey, United Kingdom; Mario A. Eisenberger, Johns Hopkins University-School of Medicine, Oncology Center, Baltimore, MD; Abderrahim Fandi and Shaoyi Li, Celgene Corporation, Summit, NJ; David I. Quinn, University of Southern California Norris Cancer Center, Los Angeles; Eric J. Small, University of California San Francisco, San Francisco, CA; Celestia S. Higano, University of Washington, Seattle, WA; and Michael J. Morris, Memorial Sloan-Kettering Cancer Center New York, NY.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.65.7270
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.65.7270DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872320PMC
May 2016

New and promising strategies in the management of bladder cancer.

Am Soc Clin Oncol Educ Book 2015 :105-12

From the Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute at the National Institutes of Health, Bethesda, MD; US Oncology Research, Houston, TX and Comprehensive Cancer Centers of Nevada, Las Vegas, NV; University of Colorado Cancer Center, Denver, CO.

View Article

Download full-text PDF

Source
http://meetinglibrary.asco.org/content/115000105-156
Publisher Site
http://dx.doi.org/10.14694/EdBook_AM.2015.35.105DOI Listing
February 2016

There is no current role for molecular phenotyping in metastatic castrate-resistant prostate cancer.

Clin Adv Hematol Oncol 2015 Sep;13(9):580-5

Comprehensive Cancer Centers of Nevada, University of Nevada School of Medicine, Las Vegas and Reno, Nevada.

View Article

Download full-text PDF

Source
September 2015

PD-1/PD-L1 in Renal Cell Carcinoma: Projecting the Way Forward.

Clin Genitourin Cancer 2015 Aug 14;13(4):257-260. Epub 2014 Jul 14.

US Oncology Research, Comprehensive Cancer Centers, Las Vegas, NV.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2014.07.004DOI Listing
August 2015

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.

N Engl J Med 2015 Aug 5;373(8):737-46. Epub 2015 Aug 5.

From the Department of Medicine (C.J.S.) and the Department of Biostatistics and Computational Biology (Y.-H.C.), Dana-Farber Cancer Institute, Boston; Harvard Medical School, Boston (C.J.S.); Johns Hopkins University, Baltimore (M.C., M.E.); University of Wisconsin Carbone Cancer Center (G.L., D.F.J.) and School of Medicine and Public Health (D.F.J.), Madison; Fox Chase Cancer Center, Temple University Health System, Philadelphia (Y.-N.W.); Indiana University Melvin and Bren Simon Cancer Center, Indianapolis (N.H.); Mayo Clinic, Rochester, MN (M.K.); University Hospitals Case Medical Center, Seidman Cancer Center (M.M.C.), and Cleveland Clinic Taussig Cancer Institute (J.A.G.) - both in Cleveland; University of Virginia Cancer Center, Charlottesville (R.D.); Comprehensive Cancer Centers of Nevada, Las Vegas (N.J.V.); Siteman Cancer Center, Washington University School of Medicine, St. Louis (J.P.); NorthShore University HealthSystem, Evanston, IL (D.S.); University of Michigan Comprehensive Cancer Center, Ann Arbor (M.H.); and Rutgers Cancer Institute of New Jersey, New Brunswick (R.S.D.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1503747DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562797PMC
August 2015

SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer.

J Clin Oncol 2015 May 6;33(14):1601-8. Epub 2015 Apr 6.

Evan Y. Yu, Hongli Li, Celestia S. Higano, Heather H. Cheng, and Catherine M. Tangen, Fred Hutchinson Cancer Research Center, University of Washington; Stephen R. Plymate, Harborview Medical Center, University of Washington, Seattle; Yoshio Inoue, Multicare Regional Cancer Center, Tacoma, WA; Neeraj Agarwal, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Sumanta K. Pal, City of Hope, Duarte; David I. Quinn, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; Ajjai Alva, University of Michigan, Ann Arbor; Elisabeth I. Heath, Karmanos Cancer Center, Wayne State University, Detroit, MI; Elaine T. Lam, University of Colorado, Denver, CO; Shilpa Gupta, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morisani College of Medicine, Tampa, FL; Michael B. Lilly, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC; Kim N. Chi, British Columbia Cancer Agency, University of British Columbia, Vancouver, British Columbia, Canada; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; and Ian M. Thompson Jr, University of Texas Health Science Center at San Antonio, San Antonio, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.4127DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417730PMC
May 2015

Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin.

Clin Genitourin Cancer 2015 Feb 1;13(1):e37-49. Epub 2014 Aug 1.

US Oncology Research Comprehensive Cancer Centers of Nevada, Las Vegas, NV.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2014.07.010DOI Listing
February 2015

CKD-EPI and cockcroft-gault equations identify similar candidates for neoadjuvant chemotherapy in muscle-invasive bladder cancer.

PLoS One 2014 10;9(4):e94471. Epub 2014 Apr 10.

Division of Urology, Department of Surgery, City of Hope Comprehensive Cancer Center, Duarte, California, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0094471PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3983198PMC
December 2014

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.

Nature 2014 Nov;515(7528):558-62

University of Nevada School of Medicine and US Oncology/Comprehensive Cancer Centers of Nevada, 3730 S. Eastern Avenue, Las Vegas, Nevada 89169, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature13904DOI Listing
November 2014

Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.

J Clin Oncol 2014 Oct 15;32(30):3391-9. Epub 2014 Sep 15.

Matthew R. Smith, Massachusettes General Hospital; Christopher J. Sweeney, Aymen Elfiky, Dana-Farber Cancer Institute, Boston, MA; Paul G. Corn, Christopher J. Logothetis, MD Anderson Cancer Center, Houston, TX; Dana E. Rathkopf, Howard I. Scher, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, NY; David C. Smith, Maha Hussain, University of Michigan, Ann Arbor, MI; Daniel J. George, Duke University Medical Center, Durham; Ethan M. Basch, University of North Carolina, Chapel Hill, NC; Celestia S. Higano, University of Washington, Seattle, WA; Andrea L. Harzstark, University of California San Francisco, San Francisco; Christian Scheffold, A. Douglas Laird, Frauke Schimmoller, Exelixis, South San Francisco, CA; A. Oliver Sartor, Tulane Cancer Center, Tulane University, New Orleans, LA; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Michael S. Gordon, Pinnacle Oncology Hematology, Scottsdale, AZ; Naomi B. Haas, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Johann S. de Bono, Royal Marsden Hospital, Sutton, Surrey, United Kingdom.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2014/09/15/JCO.2013.54
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2013.54.5954
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.54.5954DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383838PMC
October 2014

Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421.

J Natl Cancer Inst 2014 Apr 24;106(4):dju013. Epub 2014 Feb 24.

Affiliations of authors: University of California Davis Comprehensive Cancer Center, Sacramento, CA (PNL, PCM); Southwest Oncology Group Statistical Center, Seattle, WA (BE, CT); University of Southern California Norris Cancer Center, Los Angeles, CA (DIQ, AG); USDA Western Human Nutrition Center at University of California Davis, Davis, CA (EG, MVL); City of Hope, Duarte, CA (PT); University of Michigan, Ann Arbor, MI (MH), US Oncology, Las Vegas, NV (NJV); Cancer Treatment and Research Center, University of Texas, San Antonio, TX (IT).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3982883PMC
April 2014

Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.

J Clin Oncol 2014 Apr 10;32(11):1136-42. Epub 2014 Mar 10.

Amir Goldkorn, David I. Quinn, and Tong Xu, University of Southern California Keck School of Medicine and Norris Comprehensive Cancer Center, Los Angeles; Przemyslaw Twardowski, City of Hope, Duarte; Philip C. Mack and Primo Lara Jr, University of California, Davis, Sacramento, CA; Benjamin Ely and Catherine M. Tangen, Southwest Oncology Group Statistical Center; Celestia S. Higano, Puget Sound Oncology Consortium, Seattle Cancer Care Alliance, and University of Washington, Seattle, WA; Louis M. Fink, Nevada Cancer Institute; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada and US Oncology Research, Las Vegas, NV; Peter J. Van Veldhuizen, University of Kansas Cancer Center, Westwood, KS; Neeraj Agarwal, University of Utah Huntsman Cancer Institute, Salt Lake City, UT; Michael A. Carducci, Johns Hopkins Kimmel Cancer Center and Eastern Cooperative Oncology Group, Baltimore, MD; J. Paul Monk III, Ohio State University and Cancer and Leukemia Group B, Columbus, OH; Ram H. Datar and Richard J. Cote, University of Miami Miller School of Medicine, Miami, FL; Mark Garzotto, Portland Veterans Affairs Medical Center, Portland, OR; Maha Hussain, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; and Ian Murchie Thompson Jr, University of Texas Health Science Center at San Antonio, San Antonio, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.51.7417DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3970171PMC
April 2014

Radium-223 vs EBRT for multiple painful bone metastases: the data favor radium-223.

Oncology (Williston Park) 2014 Apr;28(4):296, 298

View Article

Download full-text PDF

Source
April 2014

Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.

J Clin Oncol 2014 Jan 10;32(2):129-60. Epub 2013 Dec 10.

Jyoti D. Patel, Northwestern University; Blasé Polite, University of Chicago Medicine, Chicago, IL; Lada Krilov, American Society of Clinical Oncology, Alexandria, VA; Sylvia Adams and William L. Carroll, New York University Cancer Institute; Carol Aghajanian, Mark G. Kris, and Gary K. Schwartz, Memorial Sloan-Kettering Cancer Center, New York, NY; Ethan Basch, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Marcia S. Brose, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Marcos de Lima and Mark R. Gilbert, University of Texas MD Anderson Cancer Center, Houston; Ian Thompson, University of Texas Health Science Center at San Antonio, San Antonio, TX; John L. Marshall, Lombardi Cancer Center, Washington, DC; Gregory A. Masters, Helen F. Graham Cancer Center, Newark, DE; Steven J. O'Day, Beverly Hills Health Center, Beverly Hills, CA; Sunil Sharma, Huntsman Cancer Institute, Salt Lake City, UT; Nicholas J. Vogelzang, US Oncology Research, Comprehensive Cancer Centers of Nevada, Henderson, NV; and Bruce J. Roth, Washington University in St Louis, St Louis, MO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.53.7076DOI Listing
January 2014

Two paths forward in metastatic castration-resistant prostate cancer.

Oncology (Williston Park) 2013 Jul;27(7):638-9

Comprehensive Cancer Centers of Nevada, Las Vegas, USA.

View Article

Download full-text PDF

Source
July 2013

Sequential treatment strategies and combination therapy regimens in metastatic renal cell carcinoma.

Clin Adv Hematol Oncol 2013 Mar;11(3):146-55

Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California 91010, USA.

View Article

Download full-text PDF

Source
March 2013